Evidence map›Paper›PMID 38558973›Full record

ArticlebioRxiv : the preprint server for biology2024

Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV.

Cara W Chao, Kaitlin R Sprouse, Marcos C Miranda, Nicholas J Catanzaro, Miranda L Hubbard, Amin Addetia, Cameron Stewart, Jack T Brown, Annie Dosey, Adian Valdez and 14 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 3 institutions in 1 country.

Cara W ChaoInstitute for Protein Design, University of Washington, Seattle, WA 98195, USA.ORCID 0009-0004-4824-6445
Kaitlin R SprouseDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Marcos C MirandaInstitute for Protein Design, University of Washington, Seattle, WA 98195, USA.
Nicholas J CatanzaroDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Miranda L HubbardDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Amin AddetiaDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Cameron StewartDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Jack T BrownDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Annie DoseyInstitute for Protein Design, University of Washington, Seattle, WA 98195, USA.
Adian ValdezInstitute for Protein Design, University of Washington, Seattle, WA 98195, USA.
Rashmi RavichandranInstitute for Protein Design, University of Washington, Seattle, WA 98195, USA.
Grace G HendricksInstitute for Protein Design, University of Washington, Seattle, WA 98195, USA.ORCID 0009-0008-5844-1403
Maggie AhlrichsInstitute for Protein Design, University of Washington, Seattle, WA 98195, USA.
Craig DobbinsInstitute for Protein Design, University of Washington, Seattle, WA 98195, USA.
Alexis HandInstitute for Protein Design, University of Washington, Seattle, WA 98195, USA.
Catherine TreichelInstitute for Protein Design, University of Washington, Seattle, WA 98195, USA.
Isabelle WilloughbyInstitute for Protein Design, University of Washington, Seattle, WA 98195, USA.
Alexandra C WallsDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Andrew T McGuireDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Elizabeth M LeafInstitute for Protein Design, University of Washington, Seattle, WA 98195, USA.
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Neil P KingInstitute for Protein Design, University of Washington, Seattle, WA 98195, USA.
University of Washington · USUniversity of North Carolina at Chapel Hill · USHoward Hughes Medical Institute · US

Funding

Centers for Research on Structural Biology of Infectious Diseases: Universal Influenza Vaccine Research75N93022C00036 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI STAKER, BART · 2022 to 2025
$21.7M
Structure-based design of broadly protective coronavirus vaccinesP01AI167966 · NIAID · UNIVERSITY OF WASHINGTON · PI BALI PULENDRAN · 2022 to 2026
$15.3M
NIAID NIH HHS 75N93022C00036NIAID NIH HHS P01 AI167966
6 · The paper itself

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic betacoronavirus that causes severe and often lethal respiratory illness in humans. The MERS-CoV spike (S) protein is the viral fusogen and the target of neutralizing antibodies, and has therefore been the focus of vaccine design efforts. Currently there are no licensed vaccines against MERS-CoV and only a few candidates have advanced to Phase I clinical trials. Here we developed MERS-CoV vaccines utilizing a computationally designed protein nanoparticle platform that has generated safe and immunogenic vaccines against various enveloped viruses, including a licensed vaccine for SARS-CoV-2. Two-component protein nanoparticles displaying MERS-CoV S-derived antigens induced robust neutralizing antibody responses and protected mice against challenge with mouse-adapted MERS-CoV. Electron microscopy polyclonal epitope mapping and serum competition assays revealed the specificities of the dominant antibody responses elicited by immunogens displaying the prefusion-stabilized S-2P trimer, receptor binding domain (RBD), or N-terminal domain (NTD). An RBD nanoparticle vaccine elicited antibodies targeting multiple non-overlapping epitopes in the RBD, whereas anti-NTD antibodies elicited by the S-2P- and NTD-based immunogens converged on a single antigenic site. Our findings demonstrate the potential of two-component nanoparticle vaccine candidates for MERS-CoV and suggest that this platform technology could be broadly applicable to betacoronavirus vaccine development.

Identifiers

PMID38558973
PMCPMC10979991
OpenAlexW4392860450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.